Get the Stockscreener App
28.36
1.58%
0.44
After Hours:
28.36
Septerna Inc stock is traded at $28.36, with a volume of 346.80K.
It is up +1.58% in the last 24 hours and up +9.67% over the past month.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
See More
Previous Close:
$27.92
Open:
$27.93
24h Volume:
346.80K
Relative Volume:
1.08
Market Cap:
$1.28B
Revenue:
$45.95M
Net Income/Loss:
$-48.88M
P/E Ratio:
-25.48
EPS:
-1.1129
Net Cash Flow:
$109.67M
1W Performance:
+5.23%
1M Performance:
+9.67%
6M Performance:
+10.95%
1Y Performance:
+199.16%
1-Day Range:
$27.93
$29.89
1-Week Range:
$25.79
$29.89
52-Week Range:
$9.045
$32.63
Septerna Inc Stock (SEPN) Company Profile
Name
Septerna Inc
Sector
Industry
Phone
650-338-3533
Address
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
28.36 | 1.26B | 45.95M | -48.88M | 109.67M | -1.1129 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | Raymond James | Strong Buy |
| Dec-15-25 | Initiated | Truist | Buy |
| Nov-14-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-23-25 | Initiated | H.C. Wainwright | Buy |
| Feb-18-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-19-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-19-24 | Initiated | JP Morgan | Overweight |
| Nov-19-24 | Initiated | TD Cowen | Buy |
| Nov-19-24 | Initiated | Wells Fargo | Overweight |
View All
Septerna Inc Stock (SEPN) Latest News
SEPN Q1 2026 Earnings: Smaller-Than-Expected Loss Amidst Pipeline ProgressEarnings Revision Downgrade - Newser
SEPN Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineExpert Momentum Signals - Newser
Septerna Inc. (SEPN) Q1 2026 Earnings: Smaller-than-Expected Loss Drives Positive Market ResponseCommunity Pattern Alerts - Newser
Septerna Inc. (SEPN) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineROA Comparison - Newser
New Forecasts: Here's What Analysts Think The Future Holds For Septerna, Inc. (NASDAQ:SEPN) - Sahm
Septerna, Inc. (SEPN) Competitors - Meyka
Septerna (SEPN) Q1 2026 Crushes Forecasts — EPS $-0.19 vs $-0.42Free Stock Community - Newser
Why Septerna (SEPN) Is Up 11.6% After Q1 Revenue Surge And Narrowed Losses - simplywall.st
Party Time: Brokers Just Made Major Increases To Their Septerna, Inc. (NASDAQ:SEPN) Earnings Forecasts - Yahoo Finance
Earnings Update: Septerna, Inc. (NASDAQ:SEPN) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
Q2 Earnings Forecast for Septerna Issued By HC Wainwright - MarketBeat
TradingKey - TradingKey
Earnings Update: Septerna, Inc. (NASDAQ:SEPN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Septerna Inc. (SEPN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Septerna, Inc. (SEPN) reports Q1 loss, tops revenue estimates - MSN
H.C. Wainwright reiterates Septerna stock rating at buy, $40 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Septerna stock rating at buy, $40 target - Investing.com
Septerna (SEPN) Q1 Loss Narrows To US$8.6 Million Challenging Bearish Earnings Narratives - Sahm
Wells Fargo Maintains Septerna(SEPN.US) With Buy Rating, Maintains Target Price $48 - Moomoo
TD Cowen Maintains Septerna(SEPN.US) With Buy Rating - Moomoo
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results - The Manila Times
Wells Fargo Upgrades Septerna (SEPN) - MSN
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Septerna Q1 revenue rises sharply helped by Novo Nordisk collaboration - TradingView
Septerna (NASDAQ: SEPN) grows Q1 revenue to $26.5M, trims loss - Stock Titan
Septerna, Inc. 1Q 2026: Revenue $26.5M, EPS $(0.19) — 10-Q Summary - TradingView
Septerna, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Earnings Flash (SEPN) Septerna, Inc. Reports Q1 Revenue $26.5M, vs. FactSet Est of $17.0M - marketscreener.com
Septerna (SEPN) Q1 2026 revenue jumps on Novo Nordisk deal, loss narrows - Stock Titan
Septerna moves chronic hives pill toward Phase 2 after Phase 1 study - Stock Titan
HC Wainwright & Co. Maintains Septerna (SEPN) Buy Recommendation - MSN
How Analyst Upgrade and Conference Spotlight Will Impact Septerna (SEPN) Investors - Yahoo Finance
Septerna, Inc. (SEPN) Stock Analysis: Unpacking a Potential 84% Upside in the Healthcare Biotech Arena - DirectorsTalk Interviews
Should you add Septerna (SEPN) to your watchlist today? (Weakens) 2026-05-07Continuation Pattern - newser.com
Septerna to Present at Bank of America Securities Health Care Conference - The Manila Times
Septerna CEO to give webcast presentation from Las Vegas on May 12 - Stock Titan
Septerna, Inc. ($SEPN) CEO 2025 Pay Revealed - Quiver Quantitative
Stifel Maintains Septerna(SEPN.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Septerna (NASDAQ:SEPN) Now Covered by Stifel Nicolaus - MarketBeat
Septerna, Inc. (NASDAQ:SEPN) Sees Significant Growth in Short Interest - MarketBeat
Stifel Initiates Septerna(SEPN.US) With Buy Rating, Announces Target Price $43 - Moomoo
Septerna | DEF 14A: Definitive information statements - Moomoo
Septerna (NASDAQ: SEPN) details 2026 vote on directors and auditor - Stock Titan
Septerna, Inc. (SEPN) reports Q4 loss, tops revenue estimates - MSN
[ARS] Septerna, Inc. SEC Filing - Stock Titan
Septerna (SEPN) price target increased by 34.39% to 46.41 - MSN
Septerna Inc Stock (SEPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):